VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027
VivoSim Labs, Inc. reported receiving a $5 million milestone payment from Eli Lilly linked to the advancement of a drug acquired from VivoSim's inflammatory bowel disease program. The company projects over 500% revenue growth in fiscal year 2027 driven by strong customer adoption of its innovative NAM-based 3D human cellular models for preclinical …